RUNX1 and its understudied role in breast cancer

Cell Cycle

Volumn 10, Issue 20, 2011, Pages 3461-3465

  Janes, Kevin A ^a  

^a University of Virginia   (United States)

Author keywords

Affymetrix; Microarray; Noise; Oxidative stress; Reactive oxygen species; Single cell; Stochastic; Triple negative

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR RUNX1;

BREAST CANCER; BREAST EPITHELIUM; CELL PROLIFERATION; GENE EXPRESSION; GENE FUSION; HEMATOPOIESIS; HUMAN; IN VIVO STUDY; MORPHOGENESIS; NONHUMAN; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 80055108192     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.20.18029     Document Type: Review

References (55)

1. Meyers S, Downing JR, Hiebert SW. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 1993; 13:6336-45; PMID:8413232.
2. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321-30; PMID:8565077; DOI:10.1016/S0092-8674(00)80986-1.
3. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997; 89:765-71; PMID:9182764; DOI:10.1016/S0092-8674(00)80259-7.
4. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109:113-24; PMID:11955451; DOI:10.1016/S0092-8674(02)00690-6.
5. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004; 23:4198-208; PMID:15156173; DOI:10.1038/sj.onc.1207755.
6. Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell 2002; 1:213-5; PMID:12086855; DOI:10.1016/S1535-6108(02)00049-1.
7. Silva FP, Morolli B, Storlazzi CT, Anelli L, Wessels H, Bezrookove V, et al. Identification of RUNX1/ AML1 as a classical tumor suppressor gene. Oncogene 2003; 22:538-47; PMID:12555067; DOI:10.1038/ sj.onc.1206141.
8. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991; 88:10431-4; PMID:1720541; DOI:10.1073/pnas.88.23.10431.
9. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005; 96:484-9; PMID:16052475; DOI:10.1002/ jcb.20557.
10. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25:589-600; PMID:17165130; DOI:10.1007/s10555-006-9032- 0.
11. Wang CC, Jamal L, Janes KA. Normal morphogenesis of epithelial tissues and progression of epithelial tumors. Wiley Interdiscip Rev Syst Biol Med 2011; In press; PMID:21898857; DOI:10.1002/wsbm.159.
12. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development. J Mammary Gland Biol Neoplasia 2000; 5:227-41; PMID:11149575; DOI:10.1023/A:1026499523505.
13. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007; 128:309-23; PMID:17254969; DOI:10.1016/j.cell.2006.12. 029.
14. Wang L, Brugge JS, Janes KA. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 2011; 108:E803-12; DOI:10.1073/pnas.1103423108; PMID:21873240.
15. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091-6; PMID:20190568; DOI:10.4161/cc.9.6.11035.
16. Wang H, Cui J, Bauzon F, Zhu L. A comparison between Skp2 and FOXO1 for their cytoplasmic localization by Akt1. Cell Cycle 2010; 9:1021-2; PMID:20160512; DOI:10.4161/cc.9.5.10916.
17. Janes KA, Wang CC, Holmberg KJ, Cabral K, Brugge JS. Identifying single-cell molecular programs by stochastic profiling. Nat Methods 2010; 7:311-7; PMID:20228812; DOI:10.1038/nmeth.1442.
18. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009; 69:6807-14; PMID:19690135; DOI:10.1158/0008-5472.CAN- 09-1471.
19. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27; PMID:17157791; DOI:10.1016/j.ccr.2006.10.008.
20. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30:256-68; PMID:12798140; DOI:10.1016/S1046- 2023(03)00032-X.
21. Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004; 23:4802-12; PMID:15538382; DOI:10.1038/ sj.emboj.7600476.
22. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419:316-21; PMID:12239572; DOI:10.1038/nature01036.
23. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, et al. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009; 8:3663-7; PMID:19901553; DOI:10.4161/cc.8.22.9957.
24. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, et al. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2009; 106:13433-8; PMID:19666576; DOI:10.1073/ pnas.0906455106.
25. Uhlén M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005; 4:1920- 32; PMID:16127175; DOI:10.1074/mcp.M500279-MCP200.
26. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33:49-54; PMID:12469122; DOI:10.1038/ng1060.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; DOI:10.1016/j.cell.2011.02.013.
28. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10:1014-24; PMID:1588366.
29. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14:818-29; PMID:18539112; DOI:10.1016/j.devcel. 2008.05.009.
30. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005; 24:8277-90; PMID:16116478; DOI:10.1038/ sj.onc.1208991.
31. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 2004; 5:47; PMID:15260889; DOI:10.1186/1471-2164-5-47.
32. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26:2568-81; PMID:18487574; DOI:10.1200/ JCO.2007.13.1748.
33. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, et al. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS ONE 2010; 5:9201; PMID:20169162; DOI:10.1371/journal. pone.0009201.
34. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; DOI:10.1038/35021093.
35. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74; PMID:11553815; DOI:10.1073/ pnas.191367098.
36. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10:65; PMID:18662380; DOI:10.1186/bcr2124.
37. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14:8010-8; PMID:19088017; DOI:10.1158/1078-0432.CCR-08-1208.
38. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; DOI:10.1158/1078-0432.CCR-06- 3045.
39. Schmelzle T, Mailleux AA, Overholtzer M, Carroll JS, Solimini NL, Lightcap ES, et al. Functional role and oncogene-regulated expression of the BH3- only factor Bmf in mammary epithelial anoikis and morphogenesis. Proc Natl Acad Sci USA 2007; 104:3787-92; PMID:17360431; DOI:10.1073/ pnas.0700115104.
40. Radtke I, Mullighan CG, Ishii M, Su X, Cheng J, Ma J, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci USA 2009; 106:12944-9; PMID:19651601; DOI:10.1073/pnas. 0903142106.
41. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, et al. Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 1995; 23:2762- 9; PMID:7651838; DOI:10.1093/nar/23.14.2762.
42. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63; PMID:19015660; DOI:10.1038/ nrg2484.
43. Swiers G, de Bruijn M, Speck NA. Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int J Dev Biol 2010; 54:1151-63; PMID:20711992; DOI:10.1387/ijdb.103106gs.
44. Harada H, Harada Y. Point mutations in the AML1/ RUNX1 gene associated with myelodysplastic syndrome. Crit Rev Eukaryot Gene Expr 2005; 15:183- 96; PMID:16390315.
45. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005; 106:494- 504; PMID:15784726; DOI:10.1182/blood-2004- 08-3280.
46. Wang X, Blagden C, Fan J, Nowak SJ, Taniuchi I, Littman DR, et al. Runx1 prevents wasting, myofibrillar disorganization and autophagy of skeletal muscle. Genes Dev 2005; 19:1715-22; PMID:16024660; DOI:10.1101/gad.1318305.
47. Osorio KM, Lee SE, McDermitt DJ, Waghmare SK, Zhang YV, Woo HN, et al. Runx1 modulates developmental, but not injury-driven, hair follicle stem cell activation. Development 2008; 135:1059-68; PMID:18256199; DOI:10.1242/dev. 012799.
48. Chen CL, Broom DC, Liu Y, de Nooij JC, Li Z, Cen C, et al. Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron 2006; 49:365-77; PMID:16446141; DOI:10.1016/j.neuron. 2005.10.036.
49. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R, Hennighausen L. Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Res 2001; 10:545-53; PMID:11817542; DOI:10.1023/A:1013063514007.
50. Cardiff RD, Moghanaki D, Jensen RA. Genetically engineered mouse models of mammary intraepithelial neoplasia. J Mammary Gland Biol Neoplasia 2000; 5:421-37; PMID:14973386; DOI:10.1023/A:1009534129331.
51. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, et al. AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell 2011; 146:697-708; PMID:21884932; DOI:10.1016/j.cell.2011.07. 032.
52. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136:823-37; PMID:19269363; DOI:10.1016/j.cell.2009.02.024.
53. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; DOI:10.1038/nature03443.
54. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; DOI:10.1038/nature03445.
55. Guirouilh-Barbat JK, Wilhelm T, Lopez BS. AKT1/ BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. Oncotarget 2010; 1:691-9; PMID:21321378.